Profile data is unavailable for this security.
About the company
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.
- Revenue in USD (TTM)0.00
- Net income in USD-10.77m
- Incorporated2009
- Employees2.00
- LocationKintara Therapeutics Inc9920 Pacific Heights BlvdSuite 150, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 350-4364
- Fax+1 (604) 202-1384
- Websitehttps://www.kintara.com/
More ▼
Mergers & acquisitions
| Acquired company | KTRA:NAQ since announced | Transaction value |
|---|---|---|
| TuHURA Biosciences Inc | 43.00% | -- |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals Inc | 0.00 | -48.93m | 7.11m | 22.00 | -- | 1.12 | -- | -- | -12.41 | -12.41 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -124.91 | -61.43 | -150.17 | -68.82 | -- | -- | -- | -- | -- | -4,784.14 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Trevena Inc | 3.13m | -40.29m | 7.41m | 23.00 | -- | -- | -- | 2.37 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.10k | -13.70m | 7.44m | 12.00 | -- | 0.798 | -- | 492.76 | -0.8307 | -0.8307 | 0.0008 | 0.3537 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -35.09m | 7.55m | 25.00 | -- | 0.3993 | -- | -- | -417.09 | -417.09 | 0.00 | 8.94 | 0.00 | -- | -- | 0.00 | -64.21 | -41.01 | -102.19 | -48.07 | -- | -- | -- | -- | -- | -77.43 | 0.0259 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Transcode Therapeutics Inc | 0.00 | -17.06m | 7.62m | 10.00 | -- | 1.46 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 7.72m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.95m | 7.72m | 1.00 | -- | 0.7179 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -10.77m | 7.91m | 2.00 | -- | -- | -- | -- | -5.98 | -5.98 | 0.00 | -0.0157 | 0.00 | -- | -- | 0.00 | -179.36 | -220.94 | -316.27 | -329.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Longeveron Inc | 709.00k | -22.21m | 8.13m | 23.00 | -- | 3.02 | -- | 11.46 | -10.18 | -10.18 | 0.3262 | 0.4245 | 0.0359 | -- | 4.31 | 30,826.09 | -108.45 | -63.15 | -139.35 | -75.68 | 31.17 | 33.70 | -3,020.17 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| CV Sciences Inc | 16.00m | 3.10m | 8.16m | 42.00 | 2.42 | 2.78 | 2.45 | 0.51 | 0.0206 | 0.0206 | 0.104 | 0.018 | 1.46 | 1.46 | 26.74 | 381,047.60 | 28.28 | -43.42 | 247.47 | -77.75 | 44.27 | 51.81 | 19.38 | -45.68 | 0.3733 | 13.68 | 0.0805 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Entero Therapeutics Inc | 0.00 | -16.10m | 8.20m | 15.00 | -- | 1.29 | -- | -- | -88.75 | -88.75 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -256.35 | -295.92 | -471.06 | -1,599.51 | -- | -- | -- | -- | -- | -790.91 | 0.1454 | -- | -- | -- | -7.55 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 8.33m | 137.00 | -- | 307.35 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 8.60m | 75.00 | 0.0004 | 0.00003 | 1.59 | 0.483 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Energy Finders Inc | 4.06m | -2.92m | 8.61m | 46.00 | -- | -- | -- | 2.12 | -0.272 | -0.272 | 1.52 | 3.04 | -- | -- | -- | 88,304.35 | -- | -- | -- | -- | 27.45 | -- | -71.79 | -- | 0.6706 | -12.57 | 0.564 | -- | -- | -- | -- | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Kintara Therapeutics Inc's reporting currency: US Dollar USD
0.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 31 Mar 2024 | 138.63k | 0.25% |
| G1 Execution Services LLCas of 31 Mar 2024 | 100.79k | 0.18% |
| HRT Financial LLCas of 31 Mar 2024 | 81.60k | 0.15% |
| Jane Street Capital LLCas of 31 Mar 2024 | 69.36k | 0.13% |
| Geode Capital Management LLCas of 31 Mar 2024 | 43.16k | 0.08% |
| Tower Research Capital LLCas of 31 Mar 2024 | 18.31k | 0.03% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 12.76k | 0.02% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 12.46k | 0.02% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 10.72k | 0.02% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 6.60k | 0.01% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
